AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Retinoic Acid Receptor Beta Pipeline Review, H2 2019 - ResearchAndMarkets.com

January 9, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 9, 2020--

The “Retinoic Acid Receptor Beta - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report ‘Retinoic Acid Receptor Beta - Pipeline Review, H2 2019’ outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 6, 2, 4 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Respiratory, Central Nervous System, Hematological Disorders, Immunology, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Germ Cell Tumors, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Spinal Cord Injury, Traumatic Nerve Injury and Type 2 Diabetes.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yosfb5

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005329/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/09/2020 04:54 AM/DISC: 01/09/2020 04:54 AM

http://www.businesswire.com/news/home/20200109005329/en